Engimmune Therapeutics

Engimmune Therapeutics is a biotechnology company founded in 2021 and headquartered in Switzerland. The company's slogan, "Engineering the next-generation of T cell receptor therapies against cancer," encapsulates its mission to develop innovative T-cell receptor (TCR)-based immunotherapies, including T cell therapies and biologics. Utilizing cutting-edge methods and a unique protein engineering toolbox, Engimmune has established proprietary high-throughput technology platforms to discover highly potent and safe TCR-based cell therapies and biotherapeutics, covering the entire TCR discovery value chain. Notably, the company recently secured a significant Fr.15.50MSeed Round investment on 03 May 2022, underscoring investor confidence in its vision. The investment was led by Novo Holdings, BB Pureos Bioventures, and Kinled Holding Ltd. With a focus on addressing serious human diseases with high unmet medical needs, particularly in the field of oncology, Engimmune aims to become a globally leading provider of best-in-class TCR-based therapeutics. Operating as a platform technology and product development company, Engimmune Therapeutics is situated in a brand new science park in Allschwill, Basel, ensuring proximity to Switzerland's thriving biotechnology ecosystem. Overall, the company's innovative approach and recent investment point to its potential for driving impactful advancements in the biotechnology and immunotherapy space.